Bernstein lowered the firm’s price target on Alnylam (ALNY) to $491 from $525 and keeps an Outperform rating on the shares. The firm notes Alnylam has pulled back 12% since the end of November based on third-party data suggesting the ATTR-CM launch has stalled. With recent IQVIA data telling a similar story as Symphony, Bernstein is cutting its numbers ahead of next week’s planned pre-announcement of Q4 results.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Alnylam: Buy Rating Reaffirmed as Long-Term TTR Growth and Strategic Update Offset Near-Term Amvuttra Launch Concerns
- Alnylam to invest $250M to expand manufacturing facility in Massachusetts
- Seagate, Western Digital among additions to Nasdaq-100 on 12/22
- Ionis Pharmaceuticals price target raised to $100 from $85 at Leerink
- Alnylam price target lowered to $351 from $370 at Leerink